Dr. Hamidreza Mollasalehi

Dr. Hamidreza Mollasalehi |Clyto Access

Shahid Beheshti University, Iran




Dr. Hamidreza Mollasalehi received his Ph.D. in Biochemistry (Molecular Biology) from Institute of Biochemistry and Biophysics (IBB) at University of Tehran in 2012. Currently, he is an assistant professor and faculty member of Biochemistry and Nano-biotechnology department of Protein Research Center (PRC) at ShahidBeheshti University. With a multidisciplinary background, Dr. Mollasalehi is working on cutting-edge research projects in molecular biology, molecular genetics and nano-biotechnology. His research covers mainly on molecular detection of cells including prokaryotic and eukaryotic pathogens based on targeting micro/macromolecules in order to pave the way for accurate therapy. It mainly emphases on developing biosensors and innovative diagnostic devices/kits using ultrastructure micro/nanotechnology materials and tools for clinical and health applications. He is very keen on analytical biochemistry and developing new approaches/solutions for common problems to develop next generation methodologies in life sciences. He has more than a decade of extensive experience in teaching biochemistry, molecular biology, metabolic regulation, English as Foreign Language (EFL) and also near a decade of research in the corresponding field of expertise. Dr. Mollasalehi has authored papers in journals such as Analytical Biochemistry, Biosensors & Bioelectronics, AnalyticaChimicaActa, Biotechnology letters, Journal of Nanoparticle Research, Molecular and Cellular Biochemistry.



Title: Development of a Nanoprobe-biosensing approach for direct early-phase detection of cancer cells


An appropriate detection method for simple and rapid differentiation of cancercells at early stages is of high demand. Nanobiosensingapproaches based on developing specific probes could provide ideal molecular detection method for cells and pathogens. Currently, the new approach in developing diagnostic tests is to replace conventional methods with molecular lab-on-a-chip procedures with high sensitivity and point-of-care testing. In that regard, nucleic acid testing (NAT) is of great focus because of high specificity and sensitivity. We have developed a novel detection technique based on noncoding RNA and gold nanoprobeswithboth improved targeting and detection strategies for nanodiagnosis of the most prevalent cancer cells including breast, colon, lung, prostate, pancreas, gastric, and liver. The nanoprobe-biosensingmethod was also improved to remove amplification stage and lower the overall assay time. The limit of detection (LOD) of this method was determined as2 ng/µl RNA in isolated solution which was detectable by naked eye. Results show that the proposed method could be used as a simple, rapid, sensitive platform for diagnosis of cancers before their physiological symptoms appear. This could be a promising evolution in increase the patients’ survival rate.


Related Conferences :

2nd world summit on Nanotechnology and Nanomedicine Research